Academic Journals Database
Disseminating quality controlled scientific knowledge

Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice

ADD TO MY LIST
 
Author(s): Casey Lynnette Overby | Peter Tarczy-Hornoch | Ira J. Kalet | Kenneth E. Thummel | Joe W. Smith | Guilherme Del Fiol | David Fenstermacher | Emily Beth Devine

Journal: Journal of Personalized Medicine
ISSN 2075-4426

Volume: 2;
Issue: 4;
Start page: 241;
Date: 2012;
Original page

Keywords: electronic health records | clinical decision support systems | pharmacogenomics | personalized medicine | computerized provider order entry | knowledge representation

ABSTRACT
Findings from pharmacogenomics (PGx) studies have the potential to be applied to individualize drug therapy to improve efficacy and reduce adverse drug events. Researchers have identified factors influencing uptake of genomics in medicine, but little is known about the specific technical barriers to incorporating PGx into existing clinical frameworks. We present the design and development of a prototype PGx clinical decision support (CDS) system that builds on existing clinical infrastructure and incorporates semi-active and active CDS. Informing this work, we updated previous evaluations of PGx knowledge characteristics, and of how the CDS capabilities of three local clinical systems align with data and functional requirements for PGx CDS. We summarize characteristics of PGx knowledge and technical needs for implementing PGx CDS within existing clinical frameworks. PGx decision support rules derived from FDA drug labels primarily involve drug metabolizing genes, vary in maturity, and the majority support the post-analytic phase of genetic testing. Computerized provider order entry capabilities are key functional requirements for PGx CDS and were best supported by one of the three systems we evaluated. We identified two technical needs when building on this system, the need for (1) new or existing standards for data exchange to connect clinical data to PGx knowledge, and (2) a method for implementing semi-active CDS. Our analyses enhance our understanding of principles for designing and implementing CDS for drug therapy individualization and our current understanding of PGx characteristics in a clinical context. Characteristics of PGx knowledge and capabilities of current clinical systems can help govern decisions about CDS implementation, and can help guide decisions made by groups that develop and maintain knowledge resources such that delivery of content for clinical care is supported.
Affiliate Program     

Tango Rapperswil
Tango Rapperswil